The compounds have the formula(formula)where R1 means one or more substitutes of the group H, halogeno,hydroxy, alkyl, eventually substituted by hydroxy, alkoxy,alkylthio, alkylsulphinyl, nitro, cyano, polyhalogenoalkyl,polyhalohenalkoxy, phenyl, eventually substituted by one or moresubstitutes of the group halogeno, alkyl or alkoxy or carbomoyl,eventually alkylated; R2 is aliphatic group, eventually replacedby hydroxy or alkoxy; E is alkylene chain, eventually replaced byone or more alkyl groups; G is phenyl or phenyl substituted by oneor more of the substitutes alkyl, alkoxy, halogeno, hydroxy,polyhalogenalkyl, polyhalogenoalkoxy, cyano, alkylthio,alkylsulphinyl, alkylsulphonyl, phenyl, eventually substituted byone or more substitutes of the group halogeno, alkyl, alkoxy,carbomoyl, eventually alkylated, or phenyl ring with adjunctheterocyclic or aromatic carbocyclic ring. The invention is alsorelated to their pharmaceutically acceptable salts and O-acylatedderivatives of the compounds which secure lypophilic esters, beingapplicated in analgesia or in the treatment of psychoses, such asschizophrenia, the Parkinson disease, the Lesch-Nyan syndrome,disruption of attention or cognitive disorder, for freeing frommedicamentous addiction or in late dyskinesia.21 claims
TETRAHYDROISOQUINOLINE COMPOUNDS AND THEIR APPLIACTION AS THERAPUETICAL SUBSTANCES